Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2007
Business Overview: Nektar is a biopharmaceutical company focused on Pulmonary Technology and PEGylation Technology platforms. The company generates revenue through product sales, royalties, and contract research agreements with pharmaceutical partners. A significant portion of historical revenue has been derived from the Exubera inhalation powder program in collaboration with Pfizer Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Total Revenue | $56,321 | $207,254 | $147,814 |
| Net Loss | $(18,620) | $(71,804) | $(115,906) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.78) | $(1.29) |
| Cash and Cash Equivalents | $174,713 | Balance Sheet (Sep 30, 2007) | |
| Short-term Investments | $277,931 | Balance Sheet (Sep 30, 2007) | |
| Total Current Assets | $514,771 | Balance Sheet (Sep 30, 2007) | |
| Total Liabilities | $567,382 | Balance Sheet (Sep 30, 2007) | |
| Convertible Subordinated Notes (Total) | $381,627 | Balance Sheet (Sep 30, 2007) | |
| Net Cash Provided by Operating Activities | N/A (Nine Months: $39,575) |
Note: Nine-month operating cash flow improved significantly to $39.6 million provided, compared to $66.7 million used in the prior year period, driven by upfront payments from partners.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue for the nine months ended September 30, 2007, increased 40% to $207.3 million compared to $147.8 million in 2006. This increase was primarily driven by a change in revenue recognition policy for Exubera (recognizing revenue upon shipment rather than after a 60-day return period) and increased sales volumes. However, revenue for the three-month period decreased 4% year-over-year.
- Profitability: Net loss improved significantly for the nine-month period, decreasing from $115.9 million in 2006 to $71.8 million in 2007. This improvement is attributed to higher revenues and a reduction in one-time litigation settlement charges ($17.7 million recorded in 2006) and impairment charges ($1.2 million in 2006).
- Workforce Reduction: In May 2007, the company initiated a plan to reduce its workforce by approximately 25% (180 employees). Total charges associated with this plan were approximately $8.4 million, with $8.2 million recognized in the nine months ended September 30, 2007.
- Debt Repayment: The company repaid $36.0 million of 5% convertible subordinated notes in February 2007. Additionally, $66.6 million of 3.5% notes were repaid in October 2007 (subsequent to the reporting period).
Guidance, Outlook, and Material Events
Termination of Pfizer Agreement (Critical Event)
On October 18, 2007, Pfizer delivered a notice of termination of the Collaborative Development and License Agreement regarding Exubera and the next-generation inhaled insulin program. This event occurred after the reporting period but is disclosed as a subsequent event.
- Impact: The termination is expected to result in a substantial decline in revenue in 2008. Nektar anticipates no revenue from Pfizer in the second half of 2008.
- Revenue Recognition: Approximately $23.2 million of deferred up-front fees from Pfizer will be recognized as revenue in the fourth quarter of 2007 due to the termination.
- Future Strategy: Nektar is seeking a new partner to commercialize Exubera and develop next-generation insulin. Failure to secure a partner may require the company to exit the Exubera program, potentially incurring significant wind-down costs and accelerated depreciation of assets.
New Collaboration with Bayer
On August 1, 2007, Nektar entered into a co-development agreement with Bayer Healthcare LLC for NKTR-061 (inhaled amikacin). The company received a $50.0 million upfront milestone payment, recorded as deferred revenue, with potential future milestones totaling up to $175.0 million.
Risks and Contingencies
- Liquidity: As of September 30, 2007, the company held approximately $452.6 million in cash and investments against $413.2 million in indebtedness. The company expects to use cash to fund operations and repay debt, including the remaining $315.0 million in convertible notes maturing in 2012.
- Legal Proceedings: Nektar is not a named party in the Novo Nordisk vs. Pfizer patent infringement lawsuit regarding Exubera but may incur costs or indemnity claims.
- Stock-Based Compensation: The company reversed $2.8 million of previously recorded stock-based compensation expense in Q3 2007 after determining it was not probable that Exubera sales would meet a specific performance milestone.
Investor Verification Checklist
- Pfizer Termination Terms: Verify the specific financial obligations and indemnities Nektar faces regarding the termination of the Pfizer agreement and the timeline for potential wind-down costs.
- Exubera Partnership Search: Monitor progress in securing a new commercialization partner for Exubera; failure to do so could lead to asset write-downs and loss of future revenue streams.
- Debt Maturity Profile: Assess the company's ability to service the remaining $315 million convertible note due in 2012 given the projected revenue decline from the Pfizer termination.
- Bayer Milestone Realization: Track the clinical progress of NKTR-061 to determine the likelihood of achieving the remaining $125 million in potential milestone payments.
- Asset Impairment Risk: Evaluate the recoverability of Exubera-specific manufacturing assets if a new partner is not found within the next few months, as accelerated depreciation may be required.